Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia

Journal of Clinical Oncology

Volumn 30, Issue 23, 2012, Pages 2820-2822

  Cheson, Bruce D ^a   Byrd, John C ^b   Rai, Kanti R ^c   Kay, Neil E ^d   O'Brien, Susan M ^e   Flinn, Ian W ^f   Wiestner, Adrian ^g   Kipps, Thomas J ^h  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f SARAH CANNON RESEARCH INSTITUTE   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 FLUORO 3 PHENYL 2 [1 (9H PURIN 6 YLAMINO)PROPYL] 3H QUINAZOLIN 4 ONE; BENDAMUSTINE; DASATINIB; FLUORODEOXYGLUCOSE F 18; FOSTAMATINIB; GLUCOCORTICOID; IBRUTINIB; IMMUNOMODULATING AGENT; LENALIDOMIDE; LYNKINASE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OFATUMUMAB; PREDNISONE; RITUXIMAB; THALIDOMIDE; UNCLASSIFIED DRUG;

BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ASSESSMENT; CLINICAL TRIAL; CYTOPENIA; HUMAN; LYMPHOCYTOSIS; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR FLARE;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PRACTICE GUIDELINES AS TOPIC; PROTEIN KINASE INHIBITORS;

EID: 84865082196     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.3748     Document Type: Note

References (20)

1. Cheson BD, Bennett JM, Rai KR, et al: Guidelines for clinical protocols for chronic lymphocytic leukemia: Report of the NCI-sponsored working group. Am J Hematol 29:152-163, 1988
2. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996 (Pubitemid 26189840)
3. Hallek M, Cheson BD, Catovsky D, et al: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute Working Group Guidelines. Blood 111:5446-5456, 2008
4. Chanan-Khan A, Miller KC, Musial L, et al: Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study. J Clin Oncol 24:5343-5349, 2006 (Pubitemid 46623164)
5. Ferrajoli A, Lee BN, Schlette EJ, et al: Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111:5291-5297, 2008
6. Lapalombella R, Andritsos L, Liu Q, et al: Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood 115:2619-2629, 2010
7. Chanan-Khan AA, Chitta K, Ersing N, et al: Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: In vivo evidence of immune activation and antitumour response. Br J Haematol 155:457-467, 2011
8. Chanan-Khan A, Miller KC, Lawrence D, et al: Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer 117:2127-2135, 2011
9. Friedberg JW, Sharman J, Sweetenham J, et al: Inhibition of Syk with fostamatinib disodium has significant clinical activity in non Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115:2578-2585, 2010
10. Amrein PC, Attar EC, Takvorian T, et al: Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 17:2977-2986, 2011
11. Zent CS, LaPlant BR, Johnston PB, et al: The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer 116:2201-2207, 2010
12. Burger JA, Blum KA, Furman RR, et al: The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Follow-up of a phase Ib/II study. Blood 118:449-450, 2011 (abstr 983)
13. Coutre SE, Byrd JC, Furman RR, et al: Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 29:451s, 2011 (abstr 6631)
14. de Rooij MF, Kuil A, Geest CR, et al: The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119:2590-2594, 2012
15. Sharman J, de Vos S, Leonard JP, et al: A phase 1 study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, CAL-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood 119:779-780, 2011 (abstr 1787)
16. Ponader S, Chen SS, Buggy JJ, et al: The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119:1182-1189, 2012
17. Hoellenriegel J, Meadows SA, Sivina M, et al: The phosphoinositide 3″-kinase delta inhibitor CAL-101, inhibits B-cell receptor signalling and chemokine networks in chronic lymphocytic leukemia. Blood 118:3603-3612, 2011
18. Younes A, Hagenbeek A, Coiffier B: Optimising the lymphoma response criteria in the era of targeted therapy. Lancet Oncol 12:616-617, 2011
19. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007 (Pubitemid 350002966)
20. Czuczman MS, Thall A, Witzig TE, et al: Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 23:4390-4398, 2005 (Pubitemid 46207013)